Alnylam announces publication of illuminate-a phase 3 study results for lumasiran in the new england journal of medicine

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that pivotal trial results from the illuminate-a phase 3 study of lumasiran, an rnai therapeutic targeting hydroxyacid oxidase 1 (hao1) – the gene encoding glycolate oxidase (go) – for the treatment of primary hyperoxaluria type 1 (ph1), were published online in the new england journal of medicine (nejm). in november 2020, oxlumo™ (lumasiran) was approved by th
ALNY Ratings Summary
ALNY Quant Ranking